Pediatric Nephrology Unit, Advanced Pediatric Center, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Department of Pediatrics, Advanced Pediatric Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Pediatr Nephrol. 2022 Jun;37(6):1263-1275. doi: 10.1007/s00467-021-05368-2. Epub 2022 Jan 3.
Early recognition of patients at risk for severe acute kidney injury (AKI) by renal angina index (RAI) may help in the early institution of preventive measures. Objective was to evaluate performance of RAI alone or in combination with biomarkers in predicting severe AKI (KDIGO stage 2 and 3 or equivalent) and receipt of kidney replacement therapy (KRT) in critically ill children. We searched PubMed, EMBASE, Web of Sciences, and CENTRAL for studies published till May 2021. Search terms included acute kidney injury, pediatrics, adolescent, renal angina index, and biomarker. Proceedings of relevant conferences and references of included studies were also scrutinized. Two reviewers independently assessed the study eligibility. Cohort and cross-sectional studies evaluating the diagnostic performance of RAI in predicting AKI or receipt of KRT in children were included. Eligible participants were the children less than 18 years with RAI assessment on day 0 ofadmission. We followed PRISMA-DTA guidelines and used the QUADAS-2 tool for quality assessment. A bivariate model for meta-analysis was used to calculate the summary estimates of diagnostic parameters. Major outcomes were the diagnostic accuracy of RAI (≥ 8) alone or with biomarkers in predicting severe AKI and KRT receipt. Diagnostic accuracy was reported using summary sensitivity, specificity, and area under the curve (AUC). Overall, 22 studies (24 reports, 14,001 participants) were included. RAI ≥ 8 on day 0 has summary sensitivity, specificity, and AUC of 0.86 (95% CI, 0.77-0.92), 0.77 (0.68-0.83), and 0.88 (0.85-0.91) respectively for prediction of severe AKI on day 3. In comparison, a combination of RAI and urinary neutrophil gelatinase-associated lipocalin (NGAL) showed summary sensitivity, specificity, and AUC of 0.76 (0.62-0.85), 0.89 (0.74-0.96), and 0.87 (0.84-0.90) respectively for predicting severe AKI. The sensitivity, specificity, and AUC of RAI for predicting receipt of KRT were 0.82 (0.71-0.90), 0.74 (0.66-0.81), and 0.85 (0.81-0.88) respectively. In meta-regression, only the study setting (sepsis vs. heterogenous) was associated with heterogeneity. We observed substantial heterogeneity among eligible studies. Five studies had concerns in patient selection, and seven studies also had applicability concerns in patient selection for this review. Moderate certainty evidence showed that RAI ≥ 8 has good predicting ability in recognizing children at risk of severe AKI and receipt of KRT. The combination of urinary NGAL and RAI further improves the predicting ability (low-certainty evidence). Further studies are required on the context-driven assessment of novel biomarkers in the early prediction of AKI in RAI-positive children. Systematic review registration number: CRD4202122268. A higher resolution version of the Graphical abstract is available as Supplementary information.
早期识别有发生严重急性肾损伤(AKI)风险的患者,通过肾绞痛指数(RAI)可能有助于早期采取预防措施。本研究的目的是评估 RAI 单独或联合生物标志物在预测严重 AKI(KDIGO 第 2 期和 3 期或等效)和接受肾脏替代治疗(KRT)方面的表现。我们在 PubMed、EMBASE、Web of Sciences 和 CENTRAL 中检索了截至 2021 年 5 月发表的研究。搜索词包括急性肾损伤、儿科、青少年、肾绞痛指数和生物标志物。还仔细审查了相关会议的会议记录和纳入研究的参考文献。两名评审员独立评估了研究的合格性。纳入了评估 RAI 在预测儿童 AKI 或接受 KRT 方面的诊断性能的队列研究和横断面研究。合格的参与者为年龄小于 18 岁的儿童,在入院第 0 天进行 RAI 评估。我们遵循 PRISMA-DTA 指南,并使用 QUADAS-2 工具进行质量评估。使用双变量模型进行荟萃分析,以计算诊断参数的汇总估计值。主要结局是 RAI(≥8)单独或与生物标志物预测严重 AKI 和 KRT 接受的诊断准确性。诊断准确性通过汇总敏感性、特异性和曲线下面积(AUC)报告。总体而言,共纳入了 22 项研究(24 份报告,14001 名参与者)。入院第 0 天的 RAI≥8 对第 3 天严重 AKI 的预测的汇总敏感性、特异性和 AUC 分别为 0.86(95%CI,0.77-0.92)、0.77(0.68-0.83)和 0.88(0.85-0.91)。相比之下,RAI 与尿中性粒细胞明胶酶相关脂质运载蛋白(NGAL)的联合应用对预测严重 AKI 的汇总敏感性、特异性和 AUC 分别为 0.76(0.62-0.85)、0.89(0.74-0.96)和 0.87(0.84-0.90)。RAI 预测 KRT 接受的敏感性、特异性和 AUC 分别为 0.82(0.71-0.90)、0.74(0.66-0.81)和 0.85(0.81-0.88)。在荟萃回归中,只有研究设置(脓毒症与异质性)与异质性有关。我们观察到纳入研究之间存在很大的异质性。五项研究在患者选择方面存在问题,七项研究在患者选择方面也存在适用性问题。中度确定性证据表明,RAI≥8 对识别有发生严重 AKI 和接受 KRT 风险的儿童具有良好的预测能力。尿 NGAL 和 RAI 的联合应用进一步提高了预测能力(低确定性证据)。需要进一步研究在 RAI 阳性儿童中基于特定情况评估新型生物标志物在 AKI 早期预测中的作用。系统评价注册号:CRD4202122268。可在补充信息中查看图形摘要的高分辨率版本。